Abstract

Influenza B virus (IBV) is considered a major respiratory pathogen responsible for seasonal respiratory disease in humans, particularly severe in children and the elderly. Seasonal influenza vaccination is considered the most efficient strategy to prevent and control IBV infections. Live attenuated influenza virus vaccines (LAIVs) are thought to induce both humoral and cellular immune responses by mimicking a natural infection, but their effectiveness has recently come into question. Thus, the opportunity exists to find alternative approaches to improve overall influenza vaccine effectiveness. Two alternative IBV backbones were developed with rearranged genomes, rearranged M (FluB-RAM) and a rearranged NS (FluB-RANS). Both rearranged viruses showed temperature sensitivity in vitro compared with the WT type B/Bris strain, were genetically stable over multiple passages in embryonated chicken eggs and were attenuated in vivo in mice. In a prime-boost regime in naïve mice, both rearranged viruses induced antibodies against HA with hemagglutination inhibition titers considered of protective value. In addition, antibodies against NA and NP were readily detected with potential protective value. Upon lethal IBV challenge, mice previously vaccinated with either FluB-RAM or FluB-RANS were completely protected against clinical disease and mortality. In conclusion, genome re-arrangement renders efficacious LAIV candidates to protect mice against IBV.

Highlights

  • Influenza B viruses (IBVs) in the Orthomyxoviridae family were first isolated in 1940 in Irvington, NY [1]

  • IBVs are enveloped by a host-derived lipid bilayer and contain eight segments of single-stranded, negative-sense RNA [2] that encode for at least 11 proteins: polymerase basic 1 (PB1), polymerase basic 2 (PB2), polymerase acidic (PA), hemagglutinin (HA, surface glycoprotein), nucleoprotein (NP), neuraminidase (NA, surface glycoprotein), NB, matrix protein 1 (M1), matrix protein 2 (BM2), non-structural protein 1 (NS1), and non-structural protein 2 (NS2) [3,4,5,6,7]

  • We developed an alternative influenza B virus Live attenuated influenza virus vaccines (LAIVs) based on amino acid mutations on the PB1 segment with or without a C-terminal hemagglutination assay (HA) tag

Read more

Summary

Introduction

Influenza B viruses (IBVs) in the Orthomyxoviridae family were first isolated in 1940 in Irvington, NY [1]. IBVs are of public health relevance thanks to their association with severe respiratory disease in humans, in pediatric and elderly populations. The incidence of IBV infections varies from season to season, linked to 0.69–61% of the influenza-induced pediatric mortalities registered in the United States from 2004 to 2020 [11]. During the 2019–2020 influenza season, IBV showed an early onset and the incidence of IBV infections in the United States increased compared with previous seasons. Compared with the 2018–2019 influenza season in which about 7% of influenza-positive samples corresponded to IBV [12],

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call